Trial Profile
First human trial of KP 511 for the treatment of severe pain
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Asalhydromorphone (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Zevra Therapeutics
- 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
- 10 May 2016 According to a KemPharm media release, KP511 has been granted Fast Track designation by the US FDA. KemPharm plans to seek approval of KP511/ER under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act with an anticipated New Drug Application (NDA) submission as early as 2018.
- 10 May 2016 Status changed from not yet recruiting to recruiting, according to a KemPharm media release.